Shilpa Medicare receives import alert from USFDA; Stock ends 9% down

The Company is committed to address the concerns raised by the USFDA and will work with the USFDA to resolve the issues at the earliest.

Feb 18, 2021 03:02 IST India Infoline News Service

Shilpa Medicare
Shilpa Medicare Limited, a global brand in manufacturing and supplying of affordable API has informed that the Company has received an Import Alert 66-40 on 17th February 2021, pursuant to the USFDA inspection of the Unit 4, Jadcherla, Telangana facility from 13th - 20th February and 24th- 25th February.

The Company further informs that three products have been exempted from the Import Alert - Azacitidine for Injection, Cyclophosphamide Capsules and Erlotinib Tablets.

The Company is committed to address the concerns raised by the USFDA and will work with the USFDA to resolve these issues at the earliest. They uphold quality and compliance with utmost importance and are committed to maintaining cGMP and quality standards across all Shilpa facilities.

Shilpa Medicare ended at Rs386 down by Rs40.1 or 9.41% from its previous closing of Rs426.10 on the BSE.

Related Story

Open Free Demat Account (Rs699)